Forian 2025 Q2 Earnings Remarkable Turnaround with 108.8% Net Income Surge
Generado por agente de IAAinvest Earnings Report Digest
viernes, 15 de agosto de 2025, 1:35 am ET1 min de lectura
FORA--
Forian (FORA) reported its fiscal 2025 Q2 earnings on August 14, 2025. The results reflect a strong turnaround, with the company posting a profit for the first time in recent quarters. The company reaffirmed its full-year guidance and highlighted continued operational progress.
Revenue
Forian’s total revenue surged by 56.5% to $7.48 million in Q2 2025, compared to $4.78 million in the same period in 2024, demonstrating robust growth.
Earnings/Net Income
The company returned to profitability with an EPS of $0.01, a significant reversal from a loss of $0.08 per share in the prior-year period, representing an 112.5% positive swing. Net income in Q2 2025 reached $224,793, a 108.8% turnaround from a net loss of $2.55 million in Q2 2024. This performance underscores Forian’s ability to turn operational improvements into financial gains. The company demonstrated a successful return to profitability and positive net income.
Price Action
Forian’s stock remained flat during the latest trading day, gained 1.05% over the past week, and was unchanged month-to-date, reflecting a mixed short-term investor sentiment.
Post-Earnings Price Action Review
A post-earnings strategy of buying ForianFORA-- shares after a revenue increase quarter-over-quarter and holding for 30 days has historically underperformed. Over the past three years, the strategy delivered a return of -60.64%, far below the benchmark’s 46.48%. This results in an excess return of -107.11% and a CAGR of -27.49%. Additionally, the strategy showed high volatility, with a maximum drawdown of 0.00% and a Sharpe ratio of -0.35, reflecting a very risky and disappointing investment approach.
CEO Commentary
Max Wygod, CEO and Executive Chairman, highlighted the company’s strong Q2 results, attributing them to continued execution, growth, and operational discipline. He emphasized Forian’s expansion of core capabilities and growing momentum in key markets, with a focus on both organic and strategic investments to enhance value across the healthcare ecosystem.
Guidance
Forian reaffirmed its full-year 2025 outlook, with revenue expected between $28 million and $30 million, and Adjusted EBITDA in the range of ($1.0) million to $1.0 million.
Additional News
On August 15, 2025, Nigeria’s Minister of Finance, Wale Edun, directed federal agencies to ensure all contracts are backed by proper warrants and expenditure authorizations, emphasizing fiscal discipline. Additionally, the U.S. government approved a $346 million foreign military sale to Nigeria, including munitions and precision weapons. Political tensions escalated in Benue State following the suspension of the State Universal Basic Education Board chairman by the state assembly.
In other developments, Médecins Sans Frontières raised alarms over 1,500 suspected cholera cases in Zamfara State, while the Lagos State Government introduced a forensic interview protocol to better protect and prosecute child sexual abuse victims.
Revenue
Forian’s total revenue surged by 56.5% to $7.48 million in Q2 2025, compared to $4.78 million in the same period in 2024, demonstrating robust growth.
Earnings/Net Income
The company returned to profitability with an EPS of $0.01, a significant reversal from a loss of $0.08 per share in the prior-year period, representing an 112.5% positive swing. Net income in Q2 2025 reached $224,793, a 108.8% turnaround from a net loss of $2.55 million in Q2 2024. This performance underscores Forian’s ability to turn operational improvements into financial gains. The company demonstrated a successful return to profitability and positive net income.
Price Action
Forian’s stock remained flat during the latest trading day, gained 1.05% over the past week, and was unchanged month-to-date, reflecting a mixed short-term investor sentiment.
Post-Earnings Price Action Review
A post-earnings strategy of buying ForianFORA-- shares after a revenue increase quarter-over-quarter and holding for 30 days has historically underperformed. Over the past three years, the strategy delivered a return of -60.64%, far below the benchmark’s 46.48%. This results in an excess return of -107.11% and a CAGR of -27.49%. Additionally, the strategy showed high volatility, with a maximum drawdown of 0.00% and a Sharpe ratio of -0.35, reflecting a very risky and disappointing investment approach.
CEO Commentary
Max Wygod, CEO and Executive Chairman, highlighted the company’s strong Q2 results, attributing them to continued execution, growth, and operational discipline. He emphasized Forian’s expansion of core capabilities and growing momentum in key markets, with a focus on both organic and strategic investments to enhance value across the healthcare ecosystem.
Guidance
Forian reaffirmed its full-year 2025 outlook, with revenue expected between $28 million and $30 million, and Adjusted EBITDA in the range of ($1.0) million to $1.0 million.
Additional News
On August 15, 2025, Nigeria’s Minister of Finance, Wale Edun, directed federal agencies to ensure all contracts are backed by proper warrants and expenditure authorizations, emphasizing fiscal discipline. Additionally, the U.S. government approved a $346 million foreign military sale to Nigeria, including munitions and precision weapons. Political tensions escalated in Benue State following the suspension of the State Universal Basic Education Board chairman by the state assembly.
In other developments, Médecins Sans Frontières raised alarms over 1,500 suspected cholera cases in Zamfara State, while the Lagos State Government introduced a forensic interview protocol to better protect and prosecute child sexual abuse victims.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios